• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
CC-671

CC-671

Product ID C086007
Cas No. 1618658-88-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $129.60 In stock
5 mg $306.70 In stock
25 mg $715.60 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.

Product Info

Cas No.

1618658-88-0

Purity

≥98%

Formula

C28H28N6O4

Formula Wt.

512.57

IUPAC Name

4-{[4-(Cyclopentyloxy)-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxy-N-methylbenzamide

Synonym

CC 671, CC671

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

C086007 MSDS PDF

Info Sheet

C086007 Info Sheet PDF

References

Riggs J., Nagy M., et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 60(21):8989-9002 (2017). PMID: 28991472.

Zhu D., Xu S., et al. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S Checkpoint. Mol Cancer Ther. 17(8):1727-38 (2018). PMID: 29866747.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • V9202

    VX-702

    p38 MAPK inhibitor.

    ≥98%
  • B4402

    Blasticidin S Hydrochloride

    Protein translation inhibitor.

    ≥98%
  • B3458

    Biopterin

    Endogenous pterin coenzyme required for release...

    ≥98%
  • N1858

    Neosolaniol

    Type A trichothecene mycotoxin produced by Fusa...

    ≥98%
  • E7579

    Estramustine Phosphate Disodium

    Nitrogen mustard and estradiol derivative; micr...

    ≥95%
  • Z161023

    β-Zearalanol

    Mycotoxin that has structural similarity to est...

    ≥98%
  • D3203

    Diallyl Tetrasulfide

    Organosulfur found in garlic; Microtubule polym...

    ≥90%
  • S8010

    [Nle11]-Substance P

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • E543721

    Ensartinib

    A third-generation ALK inhibitor.

    ≥98%
  • A5281

    Angiotensin II (4-8), human

    Endogenous peptide fragment, involved in vasoco...

    ≥95%
  • D0262

    Dapiprazole Hydrochloride

    α1-Adrenergic antagonist.

    ≥98%
  • B0396

    BAY80-6946

    p110α PI3K inhibitor.

    ≥98%
  • A1616

    AEE-788

    Inhibitor of EGFR, HER2, VEGFR2, and FLT3.

    ≥98%
  • U8000

    U-74389G

    Antioxidant shown to improve renal function.

    ≥95%
  • S771337

    STING Agonist-1

    Indirect activator of STING signaling

    ≥98%
  • P3441

    PIK-294

    p110δ PI3K inhibitor.

    ≥98%
  • E537334

    Enniatin B

    Mycotoxin contaminant found in cereal grains.

    ≥98%
  • H189921

    1,2,3,4,5,6-Hexabromocyclohexane

    JAK2 inhibitor

    ≥98%
  • U6901

    Uracil

    Endogenous pyrimidine base required for product...

    ≥98%
  • S3033

    Shikimic Acid

    Cyclohexanecarboxylic acid found in various pla...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only